Atherogenic Role of LDL(-) on Macrophages | Chapter 10 | Advanced Research in Biological Science Vol. 6

This unit assesses the inference of an inflammatory profile and the build-up of intracellular lipids in macrophages by electronegative LDL (LDL(-)). LDL(-), a modified LDL that is to say present in blood, exerts atherogenic belongings on endothelial cells and monocytes. Abundant studies focusing on LDL(-) have since existed performed, and ultimate widely accepted idea is that LDL(-) is a pool of LDL pieces modified by various mechanisms. In the study shown in this place chapter, LDL(-) and artificial-modified LDLs (oxidized, aggregated, acetylated) were increased macrophages derived from THP1 monocytes over-meaning CD14 (THP1-CD14). Then, cytokine release, cell distinction, lipid accumulation, and deoxyribonucleic acid expression were measured by ELISA, flow cytometry, thin-coating chromatography, and real-period PCR, respectively. Compared to added modified LDLs, LDL(-) induced THP1-CD14 macrophages to produce more cytokines. Additionally, LDL(-) stimulated semantic alterations linked to mature macrophages. HDL and antagonistic-TLR4 were added to compensate these effects. Macrophages ingested abundant amounts of LDL(-), which was the main inventor of intracellular lipid buildup in lipid droplets improved in triglycerides. In contrast to redness, the addition of anti-TLR4 had no effect on lipid aggregation, thus suggesting an rude answer pathway alternative to TLR4. In our study, compared to additional in vitro-reduced LDLs, LDL(-) was the main inductor of GM-CSF, IL6, and IL10 release, and it had a similar effect on IL1 β than oxLDL. This occurred in the deficiency of changes in cell increase or mortality. In this regard, LDL(-) upregulated the verbalization of the scavenger receptors CD36 and LOX-1, in addition to several genes involved in TG build-up. In summary, LDL(-) promoted macrophage distinction, inflammation, and triglyceride-enriched lipid beads formation in THP1-CD14 macrophages, presumably through different receptors. The complex interaction 'tween these pathways should be tried in future studies. Taken together, our judgments highlight new meaningful actions of LDL(-) on macrophage activation in the framework of the development of atherosclerosis.

Author(s) Details:

Núria Puig,
Cardiovascular Biochemistry, Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain and Department of Biochemistry and Molecular Biology, Faculty of Medicine, Building M, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Barcelona, Spain.

Berta Casaldàliga,
Cardiovascular Biochemistry, Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain and Department of Biochemistry and Molecular Biology, Faculty of Medicine, Building M, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Barcelona, Spain.

Pol Camps-Renom,
Department of Neurology, Stroke Unit, Hospital de la Santa Creu i Sant Pau and IIB-Sant Pau, Barcelona, Spain.

Francesc Jiménez-Altayó,
Department of Pharmacology, Neuroscience Institute, Faculty of Medicine, UAB, Cerdanyola del Vallès, Barcelona, Spain.

Elena Jiménez-Xarrié,
Department of Neurology, Stroke Unit, Hospital de la Santa Creu i Sant Pau and IIB-Sant Pau, Barcelona, Spain.

Jose Luis Sánchez-Quesada,
Cardiovascular Biochemistry, Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain and CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Madrid, Spain.

Sonia Benitez,
Cardiovascular Biochemistry, Biomedical Research Institute Sant Pau (IIB-Sant Pau), Barcelona, Spain and CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Madrid, Spain.

Please see the link here: https://stm.bookpi.org/ARBS-V6/article/view/12843

Mycobacterial Infection and Activation of Peroxisome Proliferator-Activated Receptors (PPARs): Role of Lipid Accumulation in Infected Cells | Chapter 4 | Current Topics on Chemistry and Biochemistry Vol. 3

The current review discusses recent research that demonstrates how mycobacterial infections activate peroxisome proliferator-activated receptors (PPARs), which play a crucial role in regulating lipid metabolism, anti-inflammatory activity, and autophagy, as well as in determining the fate of bacilli. The Middle East respiratory syndrome coronavirus (MERS-CoV)-derived S glycoprotein was responsible for the PPAR- activation, which was also accompanied by the reduction of proinflammatory cytokines and the inhibition of macrophage responses. Mycobacteria's cell wall is composed of many lipids with various molecular weights. Some mycobacterial species take over host cells and promote the creation of lipid droplets to create the cellular environment required for their intracellular survival. The survival, invasion, parasitization, and growth of mycobacteria within host cells are therefore thought to depend on lipids. Their physiological functions, however, are still not completely understood. Triacyl-glycerol (TAG) and cholesterol from the host are used by mycobacteria as food sources and as a means of immune system evasion. They also affect PPAR signalling. The host-dependent process of lipid metabolism and buildup during mycobacterial infection depends heavily on PPARs.

Author(s) Details:

Kazunari Tanigawa,
Department of Molecular Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Itabashi-Ku, Tokyo 173-8605, Japan.

Yasuhiro Nakamura,
Department of Molecular Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Itabashi-Ku, Tokyo 173-8605, Japan.

Yuqian Luo,
Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Itabashi-Ku, Tokyo 173-8605, Japana and Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.

Akira Kawashima,
Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Itabashi-Ku, Tokyo 173-8605, Japan.

Mitsuo Kiriya,
Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Itabashi-Ku, Tokyo 173-8605, Japan.

Mariko Sugawara-Mikami,
Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Itabashi-Ku, Tokyo 173-8605, Japan and  West Yokohama Sugawara Dermatology Clinic, Yokohama, Kanagawa 221-0835, Japan.

Ken Karasawa,
Department of Molecular Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Itabashi-Ku, Tokyo 173-8605, Japan.

Koichi Suzuki,
Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Itabashi-Ku, Tokyo 173-8605, Japan.

Please see the link here: https://stm.bookpi.org/CTCB-V3/article/view/7498